Stonegate Capital Partners Updates Coverage on Metallus Inc (NYSE: MTUS) 4Q25
Metallus reported year end revenue of $1,158.3M, an increase of 6.9% from $1,084.0M in FY24 driven by improving market demand. Full year adj. EBITDA declined slightly to $75.6M, a 2.7% decrease from $77.7M in FY24. Net income totaled a loss of $1.2M or $0.05 per share. In the fourth quarter the Company repurchased approximately 0.1M […]
Stonegate Capital Partners Updates Coverage on Armour Residential REIT Inc. (NYSE: ARR) 4Q25
The Company ended the quarter with interest income, net income to common, and diluted EPS of $236.5M, $208.7M, and $1.86. This was a year over year increase of 55.1%, $258.1M and $2.69 respectively. This was primarily driven by the strong growth in average interest income on interest earning assets while interest cost on average interest-bearing […]
Stonegate Capital Partners Updates Coverage on Provident Financial Services Inc (NYSE: PFS) 2025 Q4
Provident Financial Services delivered another strong quarter of expanding profitability and continued operating momentum. Net income increased to $83.4M, for an EPS of $0.64, driving a 1.34% ROAA. Revenue reached a third consecutive quarterly record at $225.7M, supported by record net interest income of $197.4M and record noninterest income of $28.3M, reflecting the Company’s ability […]
Stonegate Capital Partners Updates Coverage on Incannex Healthcare Inc. (NasdaqGM: IXHL) 2Q26
Incannex continued to build the clinical and patient-reported evidence base for IHL-42X in obstructive sleep apnea (OSA), following full Phase 2 RePOSA data and exit-interview analyses. Both lowand high-dose IHL-42X achieved statistically significant reductions in ApneaHypopnoea Index (AHI) versus placebo, with maximum AHI reductions of up to 83% in the high-dose arm. Exit interviews showed […]
Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB)
AB Science is a late-stage biotech advancing masitinib, an oral, selective tyrosine kinase inhibitor designed to modulate maladaptive neuroinflammation through mast-cell and microglia/macrophage pathways. The Company is positioning masitinib as an add-on therapy across ALS, progressive MS, and AD, while maintaining earlier-stage upside through AB8939 in AML. The combination of a treatment for ALS along […]
Stonegate Capital Partners Updates Coverage on Materion Corp (NYSE: MTRN) 4Q25
Materion’s 4Q25 results underscored strong structural tailwinds across its portfolio, even as the Company worked through a temporary precision clad strip quality issue. Management highlighted accelerating semiconductor demand – particularly outside China – driven by AI, high-performance computing, and data storage, which supports a favorable mix and expands margins in Electronic Materials. Defense remains a […]
Stonegate Capital Partners Updates Coverage on Nu Skin Enterprises Inc. (NYSE: NUS) 4Q25
NUS reported revenue, adj NI, and adj EPS of $370.3M, $14.5M, and $0.29, respectively. This compares to our estimates of $380.2M, $15.1M, and $0.30, respectively. These results were at the low end of revenue guidance and the high end of EPS guidance. Rhyz delivered $48.52M of revenue, including $42.45M from Manufacturing and $6.07M from Rhyz […]
Stonegate Capital Partners Updates Coverage on Burcon Nutrascience Corporation (TSX: BU) 3Q26
Burcon’s Galesburg production facility represents a pivotal transition from development-stage operations to commercial scale, with 3Q26 revenue of $739,000 reflecting approximately 107% quarter-overquarter growth driven by protein sales and production activity at the site. Notably, the Company entered CY2025 without a production facility and exited the year meeting its revenue target, underscoring the speed of […]
Stonegate’s Impressions from DealFlow 2026
We attended the 2026 DealFlow conference and met with a group of emerging technology and critical materials companies. While business models varied across presenters, a consistent theme was that innovation lives in microcap companies, but forward-looking technology deployment is increasingly constrained by the materials, processing capacity, and regulatory pathways required to build it.
Stonegate Capital Partners Updates Coverage on Civeo Corporation (NYSE: CVEO) 3Q25
CVEO reported revenue and adj EBITDA of $170.5M and $28.8M, respectively. This compares to our/consensus estimates of $175.9M/$173.5M and $27.7M/$27.8M, respectively. The year-over-year EBITDA increase reflected continued strength in Australia and the benefit of cost-cutting initiatives in Canada. Operating cash flow totaled $13.8M, while capital expenditures were $5.6M, primarily related to maintenance of lodges and […]